Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSIBIL6ESKD clazakizumab dose-finding and cardiovascular outcomes study in dialysis-dependent ESKD
NL-OMON59422Phase 3Recruiting
- Sponsor
- CSL Behring
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and end-stage kidney disease (ESKD) comparing clazakizumab intravenous dose arm(s) with placebo / control arm (2 arms). Primary endpoints: Change from baseline in log-transformed hs-CRP and Time to first cardiovascular death or myocardial infarction. Started Aug 2026; status: recruiting.
02
Drugs
clazakizumab
03
Conditions
atherosclerotic diseaseend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NL-OMON59422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59422.